孤立性胎儿生长受限应否提供产前染色体微阵列分析?法国多中心研究
该回顾性多中心研究纳入2016年法国13个胎儿医学中心诊断的孤立性胎儿生长受限且无结构超声异常的単胎胎儿,分析同时行核型和染色体微阵列分析(CMA)的146例。CMA检出遗传异常率为7.5%(11/146,95%CI 3.3-11.8),核型正常者中CMA额外检出致病/可能致病拷贝数变异(CNV)的增益率为3.6%(95%CI 0.5-6.6)。结论支持在孤立性胎儿生长受限中除核型外应使用CMA。
要点
- 孤立性FGR中CMA检出致病/可能致病CNV率为7.5%(11/146)。
- 核型正常者CMA额外增益率为3.6%(95%CI 0.5-6.6)。
- 所有检出致病/可能致病CNV的胎儿均终止妊娠。
核心结论
- 与核型相比,CMA提高了孤立性胎儿生长受限中遗传异常的检出。
- 结果支持在孤立性胎儿生长受限中除核型外使用CMA。
研究设计与样本
- 回顾性研究,纳入2016年法国13个胎儿医学中心诊断的孤立性胎儿生长受限且无结构超声异常的単胎胎儿。
- 胎儿生长受限定义为超声报告中估测胎儿体重低于胎龄第10百分位。
- 分析对象为同时具有核型和CMA结果的146例胎儿。
主要发现
- CMA检出遗传异常率为7.5%(11/146,95%CI 3.3-11.8),包括10个致病CNV和1个可能致病CNV。
- 核型正常的139例中,5例检出致病或可能致病CNV,CMA较核型的增益率为3.6%(95%CI 0.5-6.6)。
- 所有检出致病或可能致病CNV的胎儿均终止妊娠。
- 核型正常的3例检出意义不明变异(2.1%)。
- 7例核型异常胎儿中,CMA未检出所有胎儿的18三体嵌合体。
关键数值与推荐
- CNV按美国医学遗传学与基因组学学会(ACMG)指南分为致病、可能致病、意义不明、可能良性、良性5类。
临床怎么用
- 对孤立性胎儿生长受限且无结构超声异常的胎儿,在核型分析基础上应考虑提供CMA。
- 遗传咨询时需告知CMA较核型的额外检出增益率及意义不明变异可能。
局限性
- 回顾性设计,仅146例同时具备核型和CMA结果。
- 数据来自医疗记录、超声数据库及死胎和终止妊娠后的尸检和胎盘报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Compared with standard karyotype, chromosomal microarray analysis improves the detection of genetic anomalies and is thus recommended in many prenatal indications. However, evidence is still lacking on the clinical utility of chromosomal microarray analysis in cases of isolated fetal growth restriction. OBJECTIVE: This study aimed to estimate the proportion of copy number variants detected by chromosomal microarray analysis and the incremental yield of chromosomal microarray analysis compared with karyotype in the detection of genetic abnormalities in fetuses with isolated fetal growth restriction. STUDY DESIGN: This retrospective study included all singleton fetuses diagnosed with fetal growth restriction and no structural ultrasound anomalies and referred to 13 French fetal medicine centers over 1 year in 2016. Fetal growth restriction was defined as an estimated fetal weight of <tenth percentile for gestational age identified in ultrasound reports. For this analysis, we selected fetuses who underwent invasive genetic testing with karyotype and chromosomal microarray analysis results. Data were obtained from medical records and ultrasound databases and postmortem and placental examination reports in case of spontaneous stillbirths and terminations of pregnancy. Following the American College of Medical Genetics and Genomics guidelines, copy number variants were classified into 5 groups as following: pathogenic, likely pathogenic, variant of unknown significance, likely benign, and benign. RESULTS: Of 682 referred fetuses diagnosed with isolated fetal growth restriction, both karyotype and chromosomal microarray analysis were performed in 146 fetuses. Overall, the detection rate of genetic anomalies found by chromosomal microarray analysis was estimated to be 7.5% (11 of 146 [95% confidence interval, 3.3-11.8]), including 10 copy number variants classified as pathogenic and 1 copy number variant classified as likely pathogenic. Among the 139 fetuses with normal karyotype, 5 were detected with pathogenic and likely pathogenic copy number variants, resulting in an incremental yield of 3.6% (95% confidence interval, 0.5-6.6) in chromosomal microarray analysis compared with karyotype. All fetuses detected with pathogenic or likely pathogenic copy number variants resulted in terminations of pregnancy. In addition, 3 fetuses with normal karyotype were detected with a variant of unknown significance (2.1%). Among the 7 fetuses with abnormal karyotype, chromosomal microarray analysis did not detect trisomy 18 mosaicism in all fetuses. CONCLUSION: Our study found that compared with karyotype, chromosomal microarray analysis improves the detection of genetic anomalies in fetuses diagnosed with isolated fetal growth restriction. These results support the use of chromosomal microarray analysis in addition to karyotype for isolated fetal growth restriction.
引用
- Monier I, Receveur A, Houfflin-Debarge V, et al. Should prenatal chromosomal microarray analysis be offered for isolated fetal growth restriction? A French multicenter study. Am J Obstet Gynecol. 2021. PMID: 34058167. doi:10.1016/j.ajog.2021.05.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。